High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped was healing.
Cigna Group stock has delivered a 44.4% gain over the past five years, yet the broader valuation checks still suggest the shares screen as undervalued at the recent price of US$277.51. With shorter term returns weaker, investors are left weighing a mixed share price history against a still supportive valuation read. Over five years, Cigna Group has returned 44.4%, which points to solid long term wealth creation despite more recent share price softness. Expectations for the company to keep...
CVS Health is rebuilding momentum as Aetna drives stronger profits and higher 2026 guidance, but medical costs and PBM changes could test the recovery.
Q2 earnings and buybacks put Cigna Group in focus Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total...
Investors pay particular attention to a health insurer’s second-quarter report, which reflects more medical claims data among members.
CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.
Investing.com -- Jefferies downgraded Cigna to Hold from Buy, arguing that a growing list of earnings headwinds and limited catalysts outweigh the stock's discounted valuation, while cutting its price target to $307 from $336.
Cigna Group (NYSE:CI) raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment. The company reported second-quarter total revenue of $71
Adjusted EPS of $7.78 beats expectations, leading to a full-year outlook increase to at least $30.45, as Specialty and Care Services surge 22%.
Cigna delivers an earnings and revenue beat as Cigna Healthcare fuels growth, while the company raises its 2026 EPS outlook despite higher pharmacy costs.
The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cigna (CI) delivered earnings and revenue surprises of +2.64% and +0.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com -- The Cigna Group (NYSE:CI) reported second-quarter earnings and revenue that exceeded analyst expectations, while raising its full-year outlook, though shares fell 1% premarket following the announcement.
Cigna Group will report its earnings on Thursday under its new chief executive, Brian Evanko. It’s transitioning its pharmacy benefits business to a rebate-free model.
Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.
UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.
Cigna is scheduled to post its second-quarter results later this month, and analysts project a single-digit earnings growth.
Before the stock surged, management laid out a turnaround plan for its Aetna unit that was so explicit, they practically put a price tag on it.
Cigna Group stock has delivered a 34.3% gain over the past 5 years, yet the shares have fallen 8.0% over the last year and still screen as cheap on the latest valuation checks. That mix of solid long term returns, recent share price weakness, and a high value score sets up a clear question about whether the current price around US$287.77 fairly reflects the business today. Over 5 years, Cigna Group has returned 34.3%, which points to a business that has rewarded patient shareholders even...
Cigna trades at $298.08 and has moved in lockstep with the market. Its shares have returned 7.6% over the last six months while the S&P 500 has gained 8.4%.
CVS Health’s Aetna was the third-largest provider of Medicare Advantage plans in 2025, behind UnitedHealth Group and Humana.
The Cigna Group (NYSE:CI) reported a strong start to 2026 and raised its full-year adjusted earnings outlook following first-quarter results that management said exceeded expectations in key areas, while also announcing additional portfolio changes and providing an update on its leadership transitio
Moby summary of Cigna Corporation's Q1 2026 earnings call
CI beats Q1 EPS estimates as Evernorth revenues jump 9% despite rising pharmacy costs; 2026 EPS outlook lifted to at least $30.35.
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
